Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis - Full Text View

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00076336

Purpose

This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of Hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking lamivudine.

Condition	Intervention	Phase
Hepatitis Hepatitis B, Chronic Cirrhosis	Drug: telbivudine Drug: lamivudine	Phase III

MedlinePlus related topics: Cirrhosis Hepatitis Hepatitis B

Drug Information available for: Lamivudine Telbivudine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:	Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Further study details as provided by Novartis:

Primary Outcome Measures:

Primary Outcome is a composite endpoint termed Clinical Response, defined as achievement of the following three efficacy criteria: Serum HBV DNA < 4 log10 copies/mL, Normal ALT level, Improvement or stabilization in CTP score [ Time Frame: Week 52 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Time to Clinical Response; Duration of Clinical Response; Improvement, Stabilization, and Worsening in CTP score; Improvement, Stabilization, and Worsening in a modified (3-component) CTP score [ Time Frame: Week 52 ] [ Designated as safety issue: Yes ]

Enrollment:	232
Study Start Date:	December 2003
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: telbivudine 600mg/day oral tablet for 2 years
2: Active Comparator	Drug: lamivudine 100mg/day oral tablet for 2 years

Eligibility

Ages Eligible for Study:	16 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Documented decompensated chronic hepatitis B defined by all of the following: 1. Clinical history compatible with decompensated chronic hepatitis B related cirrhosis; 2. Child-Turcotte-Pugh score > 7 points.
Evidence of hepatic cirrhosis or portal hypertension.

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Patient is pregnant or breastfeeding.
Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.
Patient previously received lamivudine, adefovir, or an investigational anti-HBV nucleoside or nucleotide analog at any time
Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before Screening for this study.

Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076336

Show 28 Study Locations

Sponsors and Collaborators

Novartis

More Information

No publications provided

Responsible Party:	( Novartis )
Study ID Numbers:	CLDT600A2301
Study First Received:	January 20, 2004
Last Updated:	January 23, 2008
ClinicalTrials.gov Identifier:	NCT00076336 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Liver Diseases
Anti-HIV Agents
Hepatitis, Chronic
Fibrosis
Hepatitis, Viral, Human
Lamivudine
Liver Cirrhosis
Antiviral Agents

Reverse Transcriptase Inhibitors
Hepatitis
Virus Diseases
Digestive System Diseases
Anti-Retroviral Agents
Hepatitis B, Chronic
Hepatitis B
DNA Virus Infections

Additional relevant MeSH terms:

Anti-Infective Agents
Liver Diseases
Anti-HIV Agents
Molecular Mechanisms of Pharmacological Action
Hepatitis, Chronic
Fibrosis
Lamivudine
Hepatitis, Viral, Human
Enzyme Inhibitors
Liver Cirrhosis
Antiviral Agents
Hepadnaviridae Infections

Pharmacologic Actions
Reverse Transcriptase Inhibitors
Hepatitis
Virus Diseases
Digestive System Diseases
Pathologic Processes
Anti-Retroviral Agents
Therapeutic Uses
Hepatitis B, Chronic
Hepatitis B
DNA Virus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 07, 2009